Scil Proteins, a Halle, Germany-based biopharmaceutical company discovering therapeutics targeting cancer and other therapeutic areas, closed a €24m financing round with its existing investor BioNet Holding.
The company intends to use the funds to advance two products into clinical Phase I over the next three years.
Led by CEO Dr. Ulrike Fiedler, Scil Proteins develops products deriving from its Affilin® platform, a fully patent protected screening technology that uses advanced selection systems to identify target-specific molecules.
The company, which has already generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas, also offers its technology to the industry for collaborative discovery and development partnerships.
FinSMEs
02/02/2011